ARTICLE | Company News

Columbia Laboratories, Invaron Pharmaceuticals sales and marketing update

August 1, 2011 7:00 AM UTC

Columbia granted Invaron Canadian commercialization rights to Striant testosterone buccal system. The buccal testosterone tablets are approved in the U.S. for testosterone replacement therapy in men for conditions associated with a deficiency or absence of endogenous testosterone. Invaron is responsible for regulatory approval. Columbia is eligible for royalties. Terms were not disclosed. ...